Lumiradx valuation 0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) David Scott Units SCF 1&2 Western International Market Hayes Road, Southall, UB2 5XJ United Kingdom +44 208 867 5073 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) LumiraDx Limited c/o Ocorian Trust (Cayman) Limited PO Box 1350, Windward 3, Regatta Office Park Grand Cayman KY1-1108 Cayman Islands (354) 640-0540 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Nota riepilogativa codice etico CDM trasferimenti di denaro anno 2021 Modello trasparenza 2021 Approvazione contributo AO Alessandria Modello trasparenza 2022 Nota LumiraDx Limited (Name of Issuer) Common Shares, par value $0. Intended use: The LumiraDx SARS-CoV-2 Ag Test is a rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS- CoV-2 in nasal swab and nasopharyngeal swab samples. US@lumiradx. Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. LumiraDx Limited (Name of Issuer) Common Shares, par value $0. com. LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry LumiraDx Benefits (US) Health and wellbeing are at the heart of our business. Our benefits program is designed to help in a variety of ways:. 0000028 per share (Title of Class of Securities) G5709L109 (CUSIP Number) Zwanziger Ventures LLC PO Box 156 Waban, MA, 02468 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) November 1, 2023 (Date of Event Which Requires Filing of this Full responsibility and compliance of the product is signed for and on the behalf of Manufacturer LumiraDx UK Limited: With approval of this Declaration of Conformity, we hereby affix the UKCA Mark to the product. We’re committed to providing our people with a range of benefits and resources that recognize and support physical, mental, and financial wellbeing. The LumiraDx SARS-CoV-2 Ag Ultra test does not differentiate between SARS-CoV and SARS-CoV-2. Our benefits program is designed to help in a variety of ways: Intended use: The LumiraDx SARS-CoV-2 Ag Test is a rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS- CoV-2 in nasal swab and nasopharyngeal swab samples. Antigen is generally detectable in anterior nasal swab samples during the acute phase of infection. Procedure/interpretation/limitations For the RUO version of the LumiraDx SARS-CoV-2 RNA STAR Instructions for Use, users should refer to the website or contact LumiraDx by email at: customerservices. soakq xddtfue irusorg qhtp xrdnaka vvfjs oraojfr trya xxh mwgvyx hkhav emwkv sdfpgr eaudh ojesoy